Application No.: 10/801,262

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (Currently amended): A pharmaceutical composition useful in alleviating pathological conditions in mammals, comprising lysine, proline, arginine, vitamin C, magnesium, green tea extract, N-acetyl-cysteine, selenium, copper, manganese and one or more of the following substances; Moylbdenum, Pottasium, Citrus Bioflavonoids, L-Carnitine, Glucosamine, Taurine, and Chondroitin Sulfate, and one pharmaceutical acceptable component selected from the group consisting of a carrier, a diluent, and an excipient, wherein the pharmaceutical composition without the acceptable component contains 7-9 wt % magnesium, 20-30 wt % ascorbic acid and 11-25 wt % green tea extract.

Claim 2 (Currently amended): A pharmaceutical composition useful in alleviating pathological conditions in mammals, comprising lysine, proline, arginine, vitamin C, magnesium, green tea extract, N-acetyl-cysteine, selenium, copper, manganese and one or more of the following substances; Moylbdenum, Pottasium, Citrus Bioflavonoids, L-Carnitine, Glucosamine, Taurine, and Chondroitin Sulfate, and one pharmaceutical acceptable component selected from the group consisting of a carrier, a diluent, and an excipient_wherein in a dose of the composition contains approximately; 25 mg of lysine, 15 mg of proline, 8 mg of arginine, 80 mg of ascorbic acid, 30 mg of magnesium, 50 mg of green tea extract, 15 mg of N-acetyl-cysteine, 5 mcg of selenium, 50mcg of copper, and 200 mcg of manganese.

Claim 3 (canceled)

Claim 4 (Currently amended): The composition of claim 1, wherein one or more of the following substances are present in approximately the following amounts; 0.5 mcg of Moylbdenum, 5 mg of Pottasium, 15 mg of Citrus Bioflavonoids, 5 mg of L-Carnitine, 25 mg of Glucosamine (N-Acetyl-D-Glucosamine), 50 mg of Taurine, and/or 15 mg of Chondroitin Sulfate.

Claim 5 (Original): The pharmaceutical composition of claim 1 wherein the pathological condition is atherosclerosis, arteriosclerosis.

Claim 6 (Original): The pharmaceutical composition of claim 1, wherein the composition is in a oral form or a parenteral form.

Claim 7 (Original): The pharmaceutical composition of claim 6, wherein the oral form is a tablet, a pill or a capsule.

Application No.: 10/801,262

Claim 8 (Original): A method for retardation of an inflammatory response in mammals, comprising the step of administering to a mammal in need of treatment an effective amount of the pharmaceutical composition of claim 1.

Claim 9 (canceled)

Claim 10 (Original): The method of claim 8, wherein the pharmaceutical composition is administered orally, intravenously, or parenterally.

Claim 11 (Original): A method for retardation of arteriosclerosis and atherosclerosis in mammals, comprising the step of administering to a mammal in need of treatment an effective amount of the pharmaceutical composition of claim 1.

Claim 12 (canceled)

Claim 13 (Original): The method of claim 11, wherein the pharmaceutical composition is administered orally, intravenously, or parenterally.